Shionogi Inc. Announces Christopher Klein as Senior Vice President, General Counsel

FLORHAM PARK, NJ, May 31, 2023 – Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Christopher Klein, Esq. as Senior Vice President, General Counsel.
Klein brings to Shionogi Inc. more than thirty years of legal and compliance leadership in the biotechnology and pharmaceutical industry. His diverse expertise spans the legal spectrum and includes overseeing corporate governance, intellectual property procurement and litigation, compliance and reorganizations. Klein joins Shionogi Inc. from RVL Pharmaceuticals in Bridgewater, New Jersey, where he served as General Counsel and Secretary.
“Chris joins Shionogi Inc. at a pivotal time in our growth. In Japan we are recognized for our R&D heritage and ongoing innovation to address unmet medical needs. As we continue to build our U.S. presence, we’re confident that Chris’ depth of experience, wealth of knowledge and business acumen will guide our ongoing transformation,” said Nate McCutcheon, President and Chief Executive Officer, Shionogi Inc. “Chris’ credentials are exemplary, and we are equally impressed with his energy and enthusiasm for building Shionogi Inc. as a company that will be known for delivering important medicines to patients in the U.S.”
“I am thrilled to be joining Shionogi Inc. and look forward to working with the organization to continue its long and successful history of developing and launching new drugs that improve patients’ lives,” said Klein.
As General Counsel and Secretary at RVL Pharmaceuticals, Klein oversaw all legal and compliance matters, including corporate governance, business development, financing and commercial product launches. Prior to RVL Pharmaceuticals, Klein served as General Counsel at Fougera Pharmaceuticals through its acquisition by Sandoz, where he managed the company’s spin out from a larger global enterprise, grew the in-house legal team to meet the company’s commercial needs and established a corporate compliance program. Prior to Fougera, Klein held the role of Deputy General Counsel at King Pharmaceuticals through its acquisition by Pfizer Inc. and held positions of increasing responsibility at Bristol-Myers Squibb where he oversaw biotechnology intellectual property and licensing. He received his J.D. from Fordham University School of Law in New York.
Klein joins Shionogi Inc.’s executive leadership team as the company continues to expand its portfolio through a combination of in-house discovery and strategic partnerships. Building on the 2019 FDA approval and successful introduction of a treatment for certain Gram-negative infections, Shionogi Inc. is developing several late-stage compounds currently in Phase 3 clinical trials, including an investigational oral antiviral for COVID-19 and an investigational compound for people with Fragile X syndrome. Shionogi Inc.’s domestic pipeline includes projects across infectious disease, CNS, metabolic disorders and oncology.
Shionogi Inc. is also actively building partnerships that advance science with the urgency that today's global health challenges demand. Learn more about current collaborations and areas of interest including in- and out-licensing, co-promotions, equity investments, divestitures and M&A.

About Shionogi Inc.

Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a Japanese research-driven pharmaceutical company. Since 1878, we have been harnessing the full potential of science to address global health challenges. Over the past six decades, we have discovered several novel antibiotics and medications for HIV and influenza. Today, we're building on our scientific legacy by providing an antibiotic for difficult-to-treat Gram-negative bacterial infections and developing an investigational oral antiviral for COVID-19. Beyond infectious disease, our pipeline includes clinical programs in Fragile X syndrome, acute ischemic stroke, metabolic disorders and oncology. Learn more at Shionogi.com.

About Shionogi & Co. Ltd.

Shionogi & Co., Ltd. is a 145-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.